Related Experiment Videos
Role of gentamicin-impregnated cement in total joint arthroplasty
K L Garvin1, E A Salvati, B D Brause
1Cornell University Medical College, New York, New York.
Abstract:
Palacos-Gentamicin (PG) was used in 130 joint arthroplasties at The Hospital for Special Surgery. At an average follow-up of 2.5 years (range, 2 to 5), the overall recurrence rate of infection was 3.8 per cent. Only one (2.0 per cent) infection occurred where the bacteria were sensitive to PG and there were no infections in the two-stage reimplantation group. There have been no adverse effects from the gentamicin and the inferior intrusion properties of the PG have not been reflected in the clinical or radiographic results.
Insights
Palacos-Gentamicin (PG) effectively treated joint arthroplasty infections with a low 3.8% recurrence rate. No adverse effects were noted, and clinical outcomes remained positive.
Area of Science:
- Orthopedic surgery
- Infectious disease management
- Biomaterials science
Background:
- Joint arthroplasty infections pose a significant challenge in orthopedic surgery.
- Effective treatment strategies are crucial to minimize recurrence and maintain patient function.
- Palacos-Gentamicin (PG) is a potential option for managing these infections.
Purpose of the Study:
- To evaluate the efficacy and safety of Palacos-Gentamicin (PG) in treating joint arthroplasty infections.
- To determine the recurrence rate of infection following PG treatment.
- To assess clinical and radiographic outcomes associated with PG use.
Main Methods:
- Retrospective analysis of 130 joint arthroplasty cases treated with Palacos-Gentamicin (PG).
- Follow-up period ranged from 2 to 5 years, with an average of 2.5 years.
- Infection recurrence rates and adverse effects were documented.
Main Results:
- Overall infection recurrence rate was 3.8%.
- Only one infection (2.0%) occurred with bacteria sensitive to PG.
- No infections were observed in the two-stage reimplantation group.
- No adverse effects related to gentamicin were reported.
- No negative impact on clinical or radiographic results was observed.
Conclusions:
- Palacos-Gentamicin (PG) demonstrates a low recurrence rate for joint arthroplasty infections.
- PG appears to be a safe treatment option with no reported adverse effects.
- Clinical and radiographic outcomes are not compromised by PG use.